drugset
drugset / Trial / NCT06852625

Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients

NCT06852625 ↗

Phase 1 Not yet recruiting 30 enrolled Fundacion Clinic per a la Recerca Biomédica
NaSingle-groupOpen-labelOther

Summary

The ATDC-PICI study is a Phase Ib, single-arm, prospective, non-randomized, multicentric trial, to evaluate the safety of ATDC cell product as adjunctive therapy to standard of care (SOC) in highly sensitized kidney transplant recipients.

Timeline

Start
2025-05
Primary completion
2028-03
Completion
2028-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Tolerogenic Dendritic Cells Cell therapy 1 cells/kg —

Indications

transplant rejection